Certara, a renowned global leader in model-informed drug development, has signed a definitive agreement to acquire Chemaxon, a prominent provider of cheminformatics software. Chemaxon’s software products are widely used for chemical structure drawing, property prediction, and analysis. These products assist research scientists worldwide in the digitization of the design, create, test, and analyze lifecycle, which is essential for the discovery of new chemical leads.
A decade-long partnership has been maintained between Certara and Chemaxon, which provides the life sciences industry with integrated solutions. This acquisition is expected to enhance Certara's software business, as Chemaxon's revenue growth profile is consistent with Certara's. Chemaxon's adjusted EBITDA margin is projected to reach Certara's corporate average by the end of 2025. Consequently, Certara will revise its 2024 financial guidance to incorporate Chemaxon's contributions, while simultaneously maintaining its adjusted EBITDA margin guidance of 31-33%.
Certara is dedicated to accelerating drug development by offering biosimulation software, technology, and services to over 2,400 clients in 66 countries, including regulated agencies, academic institutions, and biopharmaceutical industries. Chemaxon’s platforms and solutions are indispensable for managing chemical entities in agrochemicals, biotechnology, life sciences, and other research-intensive industries. With this acquisition, Certara's position as a leader in the pharmaceutical and biotech sectors is further guaranteed.
